Notably, of the 12 currently FDA approved therapeutic drugs for PCa, mitoxantrone and docetaxel were found to be therapeutic targets for one of the significantly changed proteins identified in this study – TOP2A (Table 3). The gene discussed is TOP2A; the disease is posterior cortical atrophy.